Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay

• Published in: Nature communications 2024-12, Vol.15 (1), p.10530-12
• Main Authors: Saade, Ursula, de Boer, Jasper, Scandale, Ivan, Altcheh, Jaime, Pottel, Hans, Chatelain, Eric, Zrein, Maan
• Format: Article
• Language: English
• Subjects: 49/75; 631/1647/664/1467; 631/250/255/1715; 692/308/2779/109/1941; 692/53/2421; 96/1; Adult; Antibodies, Protozoan - blood; Antiparasitic agents; Benznidazole; Chagas disease; Chagas Disease - blood; Chagas Disease - drug therapy; Chagas Disease - immunology; Clinical trials; Disease control; Drug development; Effectiveness; Enzyme-Linked Immunosorbent Assay; Female; Health services; Humanities and Social Sciences; Humans; Immunoassay; Immunoassay - methods; Male; Middle Aged; multidisciplinary; Multiplexing; Nifurtimox; Nifurtimox - therapeutic use; Nitroimidazoles - therapeutic use; Parasitic diseases; Patients; Public health; Retrospective Studies; Samples; Science; Science (multidisciplinary); Serology; Statistical analysis; Statistical methods; Statistics; Treatment Outcome; Trypanocidal Agents - therapeutic use; Trypanosoma cruzi - immunology; Vector-borne diseases
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-54910-x

Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease. Here, using samples from a randomized controlled trial, the authors show that a multiplex immunoassay (MultiCruzi), paired with statistical analysis, can predict early treatment efficacy in adult Chagas patients, suggesting that MultiCruzi could serve as an endpoint in future clinical trials.